Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.
Continue Reading9 Meters Biopharma, Inc., a clinical-stage company focused on rare and unmet needs in gastroenterology, announced their collaboration with the Celiac Disease Foundation to support clinical trial enrollment.
Continue ReadingAnokion SA announced that they have initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study.
Continue ReadingThe ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingThe Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).
Continue ReadingThe ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue Reading“Fail faster” is a saying in drug research. In 2014, the Tufts Center for the Study of Drug Development estimated that the average cost of bringing a new drug through the development pipeline and Food and Drug Administration (FDA) approval process to market is $2.6 billion. More than 90 percent of all drugs being developed…
Continue ReadingImmusanT, a biotechnology company focusing on protecting patients with celiac disease against the effects of gluten, has announced that it has secured $40 million in funding to advance its drug, Nexvax2®, into a Phase II clinical trial. Nexvax2 is a therapeutic vaccine designed to stimulate immune tolerance in patients with celiac disease. Nexvax2® is the…
Continue ReadingCeliac Disease Foundation is proud to have been a funder and to participate on the Steering Committee for the FDA Gastroenterology Regulatory Endpoints and Advancement of Therapeutics (GREAT3) workshop. Conceived by Dr. Sonia Kupfer of the University of Chicago and CDF Medical Advisory Board member Dr. Daniel Leffler of Beth Israel Deaconess Medical Center, GREAT3…
Continue Reading
